Patents by Inventor Rex Denton
Rex Denton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8481555Abstract: The disclosure generally relates to compounds of the following formula, including their salts, as well as compositions and methods of using the compounds. The compounds are prodrugs for ligands, agonists, and partial agonists for the nicotinic ?7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.Type: GrantFiled: April 29, 2011Date of Patent: July 9, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Kimberley A. Lentz, Rex Denton, James H. Cook, II, Ivar M. McDonald, Dalton King, Richard E. Olson, Nenghui Wang, Robert A. Mate, Christiana I. Iwuagwu, F. Christopher Zusi, John E. Macor, Matthew D. Hill, Haiquan Fang
-
Patent number: 8206989Abstract: The present invention relates to the biomarker TFF-3 that measures ?-secretase mediated Notch processing. TFF-3 has utility in predicting and/or determining in vivo Notch-related toxicity associated with inhibition of Notch processing mediated by ?-secretase. The reagents and methods of the invention can be utilized before, after, or concurrently with, pre-clinical, clinical, and/or post-clinical testing. The reagents and methods of the invention can be used to identify and maintain preferred doses of test compounds and thereby prevent medical complications, such as gastrointestinal cellular damage.Type: GrantFiled: June 22, 2011Date of Patent: June 26, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Rex Denton, Jere E. Meredith
-
Publication number: 20120108596Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are prodrugs for ligands, agonists, and partial agonists for the nicotinic ?7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.Type: ApplicationFiled: April 29, 2011Publication date: May 3, 2012Inventors: Kimberley A. Lentz, Rex Denton, James H. Cook, II, Ivar M. McDonald, Dalton King, Richard E. Olson, Nenghui Wang, Robert A. Mate, Christiana I. Iwuagwu, F. Christopher Zusi, John E. Macor, Matthew D. Hill, Haiquan Fang
-
Publication number: 20110250625Abstract: The present invention relates to the biomarker TFF-3 that measures ?-secretase mediated Notch processing. TFF-3 has utility in predicting and/or determining in vivo Notch-related toxicity associated with inhibition of Notch processing mediated by ?-secretase. The reagents and methods of the invention can be utilized before, after, or concurrently with, pre-clinical, clinical, and/or post-clinical testing. The reagents and methods of the invention can be used to identify and maintain preferred doses of test compounds and thereby prevent medical complications, such as gastrointestinal cellular damage.Type: ApplicationFiled: June 22, 2011Publication date: October 13, 2011Inventors: Rex Denton, Jere E. Meredith
-
Patent number: 7989208Abstract: The present invention relates to the biomarker TFF-3 that measures ?-secretase mediated Notch processing. TFF-3 has utility in predicting and/or determining in vivo Notch-related toxicity associated with inhibition of Notch processing mediated by ?-secretase. The reagents and methods of the invention can be utilized before, after, or concurrently with, pre-clinical, clinical, and/or post-clinical testing. The reagents and methods of the invention can be used to identify and maintain preferred doses of test compounds and thereby prevent medical complications, such as gastrointestinal cellular damage.Type: GrantFiled: September 2, 2009Date of Patent: August 2, 2011Assignee: Bristol-Myers Squibb CompanyInventors: Rex Denton, Jere E. Meredith
-
Publication number: 20100003692Abstract: The present invention relates to the biomarker TFF-3 that measures ?-secretase mediated Notch processing. TFF-3 has utility in predicting and/or determining in vivo Notch-related toxicity associated with inhibition of Notch processing mediated by ?-secretase. The reagents and methods of the invention can be utilized before, after, or concurrently with, pre-clinical, clinical, and/or post-clinical testing. The reagents and methods of the invention can be used to identify and maintain preferred doses of test compounds and thereby prevent medical complications, such as gastrointestinal cellular damage.Type: ApplicationFiled: September 2, 2009Publication date: January 7, 2010Inventors: Rex Denton, Jere E. Meredith
-
Patent number: 7601540Abstract: The present invention relates to the biomarker TFF-3 that measures ?-secretase mediated Notch processing. TFF-3 has utility in predicting and/or determining in vivo Notch-related toxicity associated with inhibition of Notch processing mediated by ?-secretase. The reagents and methods of the invention can be utilized before, after, or concurrently with, pre-clinical, clinical, and/or post-clinical testing. The reagents and methods of the invention can be used to identify and maintain preferred doses of test compounds and thereby prevent medical complications, such as gastrointestinal cellular damage.Type: GrantFiled: July 18, 2007Date of Patent: October 13, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Rex Denton, Jere E. Meredith
-
Publication number: 20080166723Abstract: Haplotypes in the CDK5 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CDK5 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CDK5 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.Type: ApplicationFiled: July 26, 2007Publication date: July 10, 2008Applicant: PGxHealth, LLCInventors: Jeroen Aerssens, Maria Athanasiou, Carlos Brain, Nadine Cohen, Bradley Dain, R. Rex Denton, Richard S. Judson, Vural Ozdemir, Carol R. Reed
-
Publication number: 20080020395Abstract: The present invention relates to the biomarker TFF-3 that measures ?-secretase mediated Notch processing. TFF-3 has utility in predicting and/or determining in vivo Notch-related toxicity associated with inhibition of Notch processing mediated by ?-secretase. The reagents and methods of the invention can be utilized before, after, or concurrently with, pre-clinical, clinical, and/or post-clinical testing. The reagents and methods of the invention can be used to identify and maintain preferred doses of test compounds and thereby prevent medical complications, such as gastrointestinal cellular damage.Type: ApplicationFiled: July 18, 2007Publication date: January 24, 2008Inventors: Rex Denton, Jere E. Meredith
-
Patent number: 7250258Abstract: Haplotypes in the CDK5 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CDK5 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CDK5 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.Type: GrantFiled: December 7, 2004Date of Patent: July 31, 2007Assignee: PGxHealth LLCInventors: Jeroen Aerssens, Maria Athanasiou, Carlos Brain, Nadine Cohen, Bradley Dain, R. Rex Denton, Richard S. Judson, Vural Ozdemir, Carol R. Reed
-
Patent number: 7058517Abstract: Methods, computer program(s) and database(s) to analyze and make use of gene haplotype information. These include methods, program, and database to find and measure the frequency of haplotypes in the general population; methods, program, and database to find correlation's between an individual's haplotypes or genotypes and a clinical outcome; methods, program, and database to predict an individual's haplotypes from the individual's genotype for a gene; and methods, program, and database to predict an individual's clinical response to a treatment based on the individual's genotype or haplotype.Type: GrantFiled: June 26, 2000Date of Patent: June 6, 2006Assignee: Genaissance Pharmaceuticals, Inc.Inventors: R. Rex Denton, Richard S. Judson, Gualberto RuaƱo, J. Claiborne Stephens, Andreas K. Windemuth, Chuanbo Xu
-
Publication number: 20030207284Abstract: Novel genetic variants of the Uncoupling Protein 2 (Mitochondrial, Proton Carrier) (UCP2) gene are described. Various genotypes, haplotypes, and haplotype pairs that exist in the general United States population are disclosed for the UCP2 gene. Compositions and methods for haplotyping and/or genotyping the UCP2 gene in an individual are also disclosed. Polynucleotides defined by the haplotypes disclosed herein are also described.Type: ApplicationFiled: July 16, 2002Publication date: November 6, 2003Inventors: Anne Chew, R. Rex Denton, Christopher Raleigh Gilson, Krishnan Nandabalan, Katie E. Parks
-
Publication number: 20030175710Abstract: Novel genetic variants of the Tumor Necrosis Factor Receptor Superfamily, Member 11b (Osteoprotegerin) (TNFRSF11B) gene are described. Various genotypes, haplotypes, and haplotype pairs that exist in the general United States population are disclosed for the TNFRSF11B gene. Compositions and methods for haplotyping and/or genotyping the TNFRSF11B gene in an individual are also disclosed. Polynucleotides defined by the haplotypes disclosed herein are also described.Type: ApplicationFiled: January 9, 2002Publication date: September 18, 2003Inventors: Anne Chew, R. Rex Denton, Karyn M. Bieglecki, Krishnan Nandabalan, J. Claiborne Stephens
-
Publication number: 20030165844Abstract: Novel genetic variants of the Tumor Necrosis Factor Receptor Superfamily, Member 1A (TNFRSF1A) gene are described. Various genotypes, haplotypes, and haplotype pairs that exist in the general United States population are disclosed for the TNFRSF1A gene. Compositions and methods for haplotyping and/or genotyping the TNFRSF1A gene in an individual are also disclosed. Polynucleotides defined by the haplotypes disclosed herein are also described.Type: ApplicationFiled: August 31, 2001Publication date: September 4, 2003Applicant: Genaissance Pharmaceuticals, Inc.Inventors: Alison E. Anastasio, Anne Chew, R. Rex Denton, Krishnan Nandabalan, Katie E. Parks, J. Claiborne Stephens
-
Publication number: 20030082555Abstract: Novel genetic variants of the Intercellular Adhesion Molecule 2 (ICAM2) gene are described. Various genotypes, haplotypes, and haplotype pairs that exist in the general United States population are disclosed for the ICAM2 gene. Compositions and methods for haplotyping and/or genotyping the ICAM2 gene in an individual are also disclosed. Polynucleotides defined by the sequence the haplotypes disclosed herein are also described.Type: ApplicationFiled: November 14, 2001Publication date: May 1, 2003Inventors: Anne Chew, Julie Y. Choi, R. Rex Denton, Stefanie E. Kliem, Helen H. Lee, Krishnan Nandabalan
-
Publication number: 20030078220Abstract: Polynucleotides comprising one or more of 38 novel single nucleotide polymorphisms in the human Interleukin 4 Receptor Alpha(IL4R&agr;) gene are described. Compositions and methods for detecting one or more of these polymorphisms are also disclosed. In addition, various genotypes and haplotypes for IL4R&agr; gene that exist in the population are described.Type: ApplicationFiled: November 9, 2001Publication date: April 24, 2003Inventors: Anne Chew, R. Rex Denton, Amy Duda, Krishnan Nandabalan, Joel Claiborne Stephens, Andreas K. Windemuth